No amendment to this Item is being made.

The last two paragraphs set forth under the caption "July 2024 Share Purchase Deed" within Item 6 of the Schedule 13D are hereby superseded by the paragraphs set forth below under the caption "July 2024 Share Purchase Deed," and the information set forth under the caption "March 2025 Secondary Offering" within Item 6 of the Schedule 13D is hereby superseded as set forth below under the caption "March 2025 Secondary Offering." July 2024 Share Purchase Deed Subject to the terms and conditions of the July 2024 Share Purchase Deed, in connection with the March 2025 Secondary Offering, the Issuer purchased Ordinary Shares from Pfizer, and Pfizer sold Ordinary Shares to the Issuer, having an aggregate purchase price of approximately GBP170 million (approximately $220 million at the pricing of the March 2025 Secondary Offering) (such transaction, the "March 2025 Share Buyback"). The purchase price per Ordinary Share in the March 2025 Share Buyback was equal to the offering price per Ordinary Share in the March 2025 Secondary Offering. Accordingly, a total of approximately 44 million Ordinary Shares were repurchased by the Issuer pursuant to the March 2025 Share Buyback. The March 2025 Share Buyback was conditioned on, among other things, the closing of the March 2025 Secondary Offering. The March 2025 Share Buyback closed on March 21, 2025. The foregoing description of the July 2024 Share Purchase Deed does not purport to be complete and is qualified in its entirety by reference to the actual terms of such agreement, which is filed as Exhibit 99.1 to Amendment No. 8 and is incorporated by reference herein. March 2025 Secondary Offering On March 18, 2025, Pfizer, as the seller, entered into a secondary block trade agreement (the "March 2025 Block Trade Agreement") with Citigroup Global Markets Limited, Goldman Sachs International, Merrill Lynch International, Deutsche Bank AG, acting through its London Branch (which is trading for these purposes as Deutsche Numis), and Barclays Bank PLC as the lead managers (the "Lead Managers"), and the additional managers named therein (together with the Lead Managers, the "Managers"), pursuant to which the Lead Managers agreed, severally and not jointly or jointly and severally, to use their respective reasonable endeavors to procure purchasers for up to 661,709,764 Ordinary Shares (or such other number as agreed between Pfizer and the Lead Managers) at a price to be determined pursuant to an accelerated bookbuilding process (the "March 2025 Secondary Offering"), and the Managers excluding the Lead Managers agreed, severally and not jointly or jointly and severally, to act as co-managers in connection with the March 2025 Secondary Offering. Pursuant to the terms of sale dated March 19, 2025 (the "Terms of Sale"), 617,553,920 Ordinary Shares were sold at a price of 385 pence (approximately $5.01 at the pricing of the March 2025 Secondary Offering) per Ordinary Share. Such Ordinary Shares were sold in an unregistered offering pursuant to exemptions from registration under the Securities Act of 1933, as amended. The March 2025 Secondary Offering closed on March 21, 2025. The foregoing descriptions of the March 2025 Block Trade Agreement and the Terms of Sale do not purport to be complete and are qualified in their entirety by reference to the actual terms of such agreements, which are filed as Exhibit 99.2 and Exhibit 99.3 to Amendment No. 14 and are incorporated by reference herein.

99.1 Share Purchase Deed, dated as of July 29, 2024, by and between Pfizer Inc. and the Issuer (incorporated by reference to Exhibit 99.1 to Amendment No. 8). 99.2 Secondary Block Trade Agreement, dated as of March 18, 2025, by and among Pfizer Inc., Citigroup Global Markets Limited, Goldman Sachs International, Merrill Lynch International, Deutsche Bank AG, acting through its London Branch (which is trading for these purposes as Deutsche Numis), Barclays Bank PLC, RBC Europe Limited, J.P. Morgan Securities plc, Morgan Stanley & Co. International plc and Independence Point Securities LLC (incorporated by reference to Exhibit 99.2 to Amendment No. 14). 99.3 Terms of Sale, dated as of March 19, 2025, by and among Pfizer Inc., Citigroup Global Markets Limited, Goldman Sachs International, Merrill Lynch International, Deutsche Bank AG, acting through its London Branch (which is trading for these purposes as Deutsche Numis), Barclays Bank PLC, RBC Europe Limited, J.P. Morgan Securities plc, Morgan Stanley & Co. International plc and Independence Point Securities LLC (incorporated by reference to Exhibit 99.3 to Amendment No. 14).